Join Growin Stock Community!

Biolinerx ltd.BLRX.US Overview

US StockHealthcare
(No presentation for BLRX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BLRX AI Insights

BLRX Overall Performance

BLRX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BLRX Recent Performance

-0.46%

Biolinerx ltd.

0.05%

Avg of Sector

-0.31%

S&P500

BLRX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BLRX Key Information

BLRX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BLRX Profile

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Price of BLRX

BLRX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BLRX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.68
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.04
PB Ratio
0.64
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
50.69%
Net Margin
-23.38%
Revenue Growth (YoY)
-42.09%
Profit Growth (YoY)
-57.32%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.68
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.04
PB Ratio
0.64
Price-to-FCF
-
Gross Margin
50.69%
Net Margin
-23.38%
Revenue Growth (YoY)
-42.09%
Profit Growth (YoY)
-57.32%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is BLRX's latest earnings report released?

    The most recent financial report for Biolinerx ltd. (BLRX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BLRX's short-term business performance and financial health. For the latest updates on BLRX's earnings releases, visit this page regularly.

  • What is the operating profit of BLRX?

    According to the latest financial report, Biolinerx ltd. (BLRX) reported an Operating Profit of -2.21M with an Operating Margin of -516.86% this period, representing a growth of 59.03% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BLRX's revenue growth?

    In the latest financial report, Biolinerx ltd. (BLRX) announced revenue of 427K, with a Year-Over-Year growth rate of -91.36%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does BLRX have?

    As of the end of the reporting period, Biolinerx ltd. (BLRX) had total debt of 11.38M, with a debt ratio of 0.29. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BLRX have?

    At the end of the period, Biolinerx ltd. (BLRX) held Total Cash and Cash Equivalents of 25.21M, accounting for 0.63 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BLRX go with three margins increasing?

    In the latest report, Biolinerx ltd. (BLRX) did not achieve the “three margins increasing” benchmark, with a gross margin of 80.3%%, operating margin of -516.86%%, and net margin of -228.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BLRX's profit trajectory and future growth potential.

  • What is the FCF of BLRX?

    Biolinerx ltd. (BLRX)'s Free Cash Flow (FCF) for the period is -2.12M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 78.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.